



www.e l sev ie r . com/ loca t e / pa inA critical period in the supraspinal control of pain: Opioid-dependent changes
in brainstem rostroventral medulla function in preadolescence
Gareth J. Hathway a,b,⇑, David Vega-Avelaira a, Maria Fitzgerald a
aUCL Neuroscience, Physiology and Pharmacology, University College London, London, UK
b School of Biomedical Sciences, The University of Nottingham, Nottingham, UK
Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.a r t i c l e i n f o a b s t r a c tArticle history:
Received 26 May 2011
Received in revised form 19 October 2011








Adolescence0304-3959/$36.00  2011 International Association
doi:10.1016/j.pain.2011.11.011
⇑ Corresponding author at: School of Biomedical
Nottingham, Medical School, Queens Medical Centre,
E-mail address: Gareth.Hathway@nottingham.ac.uWe have previously shown that the balance of electrically evoked descending brainstem control of spinal
nociceptive reﬂexes undergoes a switch from excitation to inhibition in preadolescent rats. Here we show
that the same developmental switch occurs when l-opioid receptor agonists are microinjected into the
rostroventral medulla (RVM). Microinjections of the l-opioid receptor agonist [D-Ala2, N-MePhe4, Gly-
ol]-enkephalin (DAMGO) into the RVM of lightly anaesthetised adult rats produced a dose-dependent
decrease in mechanical nociceptive hindlimb reﬂex electromyographic activity. However, in preadoles-
cent (postnatal day 21 [P21]) rats, the same doses of DAMGO produced reﬂex facilitation. RVM microin-
jection of d-opioid receptor or GABAA receptor agonists, on the other hand, caused reﬂex depression at
both ages. The l-opioid receptor-mediated descending facilitation is tonically active in naive preadoles-
cent rats, as microinjection of the l-opioid receptor antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-
NH2 (CTOP) into the RVM at this age decreases spinal nociceptive reﬂexes while having no effect in
adults. To test whether tonic opioid central activity is required for the preadolescent switch in RVM
descending control, naloxone hydrochloride was delivered continuously from subcutaneous osmotic
mini-pumps for 7-day periods, at various postnatal stages. Blockade of tonic opioidergic activity from
P21 to P28, but not at earlier or later ages, prevented the normal development of descending RVM inhib-
itory control of spinal nociceptive reﬂexes. Enhancing opioidergic activity with chronic morphine over P7
to P14 accelerated this development. These results show that descending facilitation of spinal nociception
in young animals is mediated by l-opioid receptor pathways in the RVM. Furthermore, the developmen-
tal transition from RVM descending facilitation to inhibition of pain is determined by activity in central
opioid networks at a critical period of periadolescence.
 2011 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.1. Introduction
Pain modulatory networks in the brain play an active role in
controlling spinal nociceptive responses so that pain perception
is inﬂuenced by our state of arousal, attention and expectation.
This supraspinal pain modulation is mediated by networks distrib-
uted throughout the limbic system and midbrain which exert their
control at the level of the dorsal horn of the spinal cord, via anti-
and pro-nociceptive descending pathways arising in the rostral
ventral medulla (RVM) [4–6,10]. The importance of endogenous
pain modulation via the RVM has been demonstrated in healthy
human subjects and in numerous laboratory studies of models of
experimental pain [8,9,11,26,44,45].for the Study of Pain. Published by
Sciences, The University of
Nottingham NG7 2UH, UK.
k (G.J. Hathway).Pain experience begins in early life and noxious stimulation
activates even the youngest newborn infant brain [33,34], but
the importance of this early experience upon adult pain processing
has been neglected in theories of pain. Responses to pain in early
life are different from those seen in adults; thermal and mechani-
cal thresholds are signiﬁcantly lower in young animals and hu-
mans, and behavioural responses to noxious stimulation are
uncoordinated and exaggerated [14]. More recently there is
increasing evidence that children’s health and pain experience
shapes their pain responses in adulthood [23,38,39]; however,
the mechanism underlying this is not known.
We have previously shown that the supraspinal control of
spinal nociceptive reﬂexes is slow to develop over the postnatal
period [14,18]. Speciﬁcally, microstimulation of RVM networks is
pronociceptive until postnatal day 21 (P21), after which time a
clear antinociception emerges [18]. The timing of this change sug-
gested that the process may be vulnerable to activity dependentElsevier B.V. All rights reserved.
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arises from the central actions of endogenous opioids. In the adult,
component nuclei of the pain-modulating circuit are linked
through the release of endogenous opioids, which inﬂuence pain
modulation by acting upon opiate receptors within the circuit,
including the RVM. Thus microinjection of morphine, l-opioid or
d-opioid receptor agonists into the adult RVM elicits analgesia by
activating descending anti-nociceptive controls of dorsal horn
excitability and microinjecting naloxone, an opiate receptor antag-
onist, in the same region is pronociceptive [12,21]. We hypothesise
here that, because RVM networks are pronociceptive before P21,
microinjection of l-opioid receptor agonists into the RVM of young
animals activates descending control of nociceptive reﬂexes, but
that the effect is facilitatory.
Endogenous opioids are known to play a role in synaptogenesis
and in brain development [28,43], their role in the growth and
development of pain pathways is not known. We hypothesise that
opioid networks have a trophic role in the maturation of supraspi-
nal pain control and that the transition from descending facilita-
tion to inhibition in the preadolescent period is dependent upon
endogenous opioid signalling in the immature brain.
Using electromyography (EMG) recordings in response to nox-
ious mechanical stimulation, we show that spinal excitability is
differentially modulated by intra-RVMmicroinjection of the l-opi-
oid receptor agonist DAMGO in preadolescent and adult rats. Using
awake behaving rats, we show that there is tonic ongoing opioid-
dependent facilitation of reﬂexes in preadolescent but not adult
rats. We further identify a critical period when this tonic endoge-
nous opioid activity determines the normal maturation of supra-
spinal pain control.Fig. 1. Method of determining spinal excitability using EMG recordings. Four von
Frey hairs are applied sequentially to the plantar surface of 1 hindpaw, and the
ﬂexor reﬂex EMG is recorded. Under basal conditions, the threshold is determined
(T) and the responses to this, to 1 hair above threshold (T+1) and to the 2 hairs
below threshold (T1 and T2), are measured and plotted as a stimulus–response
curve. The area under the curve (AUC) is calculated for each condition, and the
result is termed ‘reﬂex excitability’. The EMG response to these same 4 hairs, in all
experimental conditions in the same animal, are then remeasured, thus allowing
changes in spinal excitability to a pre-established set of noxious and innocuous
stimuli to be compared.2. Methods
All animal procedures were licensed by the UK Home Ofﬁce and
performed in accordance with the Animals (Scientiﬁc Procedures)
Act 1986. Sprague–Dawley rats were housed in cages of 6 age-
matched animals with free access to food and water. The room in
which animals were housed had a 12-hour light/dark cycle. For the
purposes of this study animals <40 days old are called juvenile or
preadolescent, and animalsP40 days old are called adult. Although
still only young adults, 40-day-old rats display all the structural and
functional properties of mature adults, weigh between 200 and
250 g, and are routinely reported in the literature as adults.
2.1. RVM microinjections and electrical stimulation
Animals were anaesthetized with isoﬂurane and mounted on a
stereotaxic frame, the skull exposed and bregma located. Stereo-
taxic coordinates for the RVM were calculated (adult: left–right
[L-R], 0 mm; anterior–posterior [A-P], 9.7 mm; dorsal–ventral [D-
V], 10 mm; P21: L-R, 0 mm; A-P, 9.2 mm; D-V, 10.0 mm) and
a 30-gauge 2.5-lL syringe (Hamilton, Reno, Nevada) inserted via
a drilled hole in the skull. Drugs were injected over a 5-minute per-
iod. The syringe was removed, and the wound closed.
The following drugs were administered by microinjection into
the RVM at doses determined from previously published studies
in adult brainstem (in parentheses): DAMGO (l-agonist, 3, 10,
and 30 ng, Sigma [22]; D[Ala]-deltorphin II, 30, 300, and 1000 ng,
Tocris, Bristol U.K. [21]); gabazine (GABAA receptor antagonist,
10 ng, Sigma [19]); CTOP (100 ng, Sigma [37]); and saline. Drugs
were applied slowly over a 5-minute injection period, in volumes
of 0.25 lL. Only 1 drug at a single dose was administered to any
animal. Dose–response studies are therefore produced from
separate groups of animals at each dose. In a separate group of rats,
naloxone hydrochloride (2 mg/kg, i.p., Sigma (Poole U.K.)) wasadministered to preadolescent (P21) rats after RVM microinjection
of DAMGO 300 ng 10 minutes previously and allowed to distribute
for 2 minutes before remeasuring evoked reﬂex activity. The
experimenter was blinded with regard to drug type.
For electrical stimulation, concentric bipolar stimulating elec-
trodes were lowered into the RVM using the coordinates above.
Trains of stimuli of 500-microsecond pulse width were applied at
10 Hz, at amplitudes ranging from 5 to 200 lA (Neurolog; Digiti-
mer, Welwyn Garden City, UK).
2.2. EMG recording
EMG recordings were performed as described previously [18].
Animals were anesthetized with isoﬂurane (2%–4%) and an endo-
tracheal cannula inserted for artiﬁcial ventilation and then
mounted on a stereotaxic frame (Kopf Instruments Tujunga, Cali-
fornia). A bipolar concentric needle electrode (Ainsworks, coventry,
UK) was inserted in the lateral biceps femoris through a small skin
incision. Such recording electrodes ensure that recorded activity is
restricted to local muscle activity in small animals. Isoﬂurane anes-
thesia was then reduced to 1.5% (Univentor 400 anesthesia unit,
Malta) and equilibrated for 20 minutes before recording. Flexion
EMG (full-wave rectiﬁed) activity was recorded following sequen-
tial (lowest to highest intensity) von Frey hair (vFh) stimulation of
the plantar surface of the foot. Because mechanical withdrawal
thresholds are signiﬁcantly lower in neonates than in adults [14],
different hairs were used in each age group. Thresholds were
determined as the von Frey hair that produced an EMG response
that was 10% greater than resting EMG activity.
Responses to 2 sub-threshold von Frey hairs (T1, T2), the
threshold hair (T) and a supra-threshold hair (T+1) were recorded
and the same 4 hairs used in all subsequent stimulation conditions
and for data analysis (described below). Each hair was applied 3
times, and the mean reading for each of the 3 presentations re-
corded. A stimulus–response curve of EMG magnitude versus
mechanical stimulus intensity was plotted, and the area under
the curve (AUC) was calculated to provide an integrated measure
of the spinal ‘‘reﬂex excitability’’ (see Fig. 1). This value was de-
noted the baseline response of the animal. Responses were normal-
ized to this baseline because of variations in background
(nonevoked) EMG activity. After RVM manipulations (electrical or
pharmacological), the EMG responses evoked by the same 4 hairs,
were remeasured and the AUC at this time (or stimulus intensity)
recalculated and compared with the baseline response. Increases in
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EMG response, whereas inhibition of EMG activity is reported as a
reduction in percent EMG response (i.e., a reduction in reﬂex excit-
ability). It should be noted that although facilitation of responses
could be very great (i.e., >100%), inhibition of EMG activity cannot
exceed 100%, and this should be considered when comparing
inhibition and facilitation in the results.
2.3. Naloxone-ﬁlled osmotic pump insertion
Alzet mini-osmotic pumps (Model 2001; Durect Corporation,
Cuppertino, CA:) were ﬁlled with a naloxone hydrochloride or nal-
oxone methiodide (Sigma) solution (0.3 mg/kg) to deliver at a rate
of 1 lL per hour for 7 days. Pumps were implanted subcutaneously
in P14, P21, or P28 rats under isoﬂurane anesthesia and to rest
upon the lower ribcage. The incision was closed with suture and
animals were returned to their home cage for 19 days, after which
EMG recordings in response to RVM electrical stimulation were
performed (see above). Depletion of drug from the pump reservoir
was conﬁrmed post mortem. In a separate study, mini-pumps that
contained morphine sulphate (0.175 mg/kg) or saline were in-
serted, as described above, into P7 rat pups. Drug was delivered
for 7 days and animals were allowed to mature until P21, when
EMG responses to RVM electrical stimulation were recorded. In
all cases, the experimenter was blinded to the drug treatment of
the animal.
2.4. Behavioural assessment of mechanical withdrawal thresholds
Animals were handled daily for 7 days before behavioural test-
ing to acclimate them to human contact and to habituate them to
the testing procedure, thereby limiting stress-induced effects. Ani-
mals were lightly restrained by the experimenter with 1 hand, and
mechanical withdrawal thresholds were measured by the applica-
tion of vFh to the dorsum of the foot. Hairs of increasing weight
were applied sequentially, lowest to highest, 5 times each, and
the ﬁrst hair to elicit a withdrawal in 2 of those 5 presentations
(40%) was considered to be the threshold. After baseline threshold
assessment, animals received an i.p. injection of naloxone hydro-
chloride (2 mg/kg), naloxone methiodide (2 mg/kg), morphine sul-
phate (2 mg/kg), CTOP (0.1 mg/kg), or saline. Animals were
returned to a holding cage and thresholds reassessed 30 minutes
after drug administration in the same way. The experimenter
was blinded to the drug that was being administered.
2.5. Immunohistochemistry
Immunohistochemistry for thel-opioid receptorwas performed
on brains from rats chronically treatedwith naloxone hydrochloride
or saline between P21 and P28. Brainstem immunohistochemistry
was performed on 40-lm frozen sections after conventional 4%
paraformaldehyde (PFA) perfusion and post-ﬁxation in 4% PFA for
1 h at 4C followed by sucrose cryoprotection for at least 2 days.
In the brainstem, mouse anti-NeuN (Chemicon, Watford, U.K.
1:1000) and rabbit anti-l-opioid receptor antibodies (Neuromics,
Edina MN 1:1000) were used with goat anti-mouse (Alexa-593)
and goat anti-rabbit (Alexa-488, Invitrogen, Paisley, U.K.) secondary
antibodies, 1:200. Immunohistochemically stained sections were
observed with a Leica IRE2 ﬂuorescence microscope and captured
using Velocity 5.5 (Perkin Elmer, UK). Four brains per treatment
groupwere processed in this way. For each brain, 6 coronal sections
at an anatomical level that included the nucleus raphemagnuswere
assessed. Total numbers of l-opioid receptor-positive cells were
counted in the RVM in each section, and the mean number of cells
was calculated for each animal (total cells counted in 6 sectionsdivided by 6). Thesemean values in each treatment groupwere then
compared statistically (discussed below).
2.6. Quantitative polymerase chain reaction
RNAwasextracted fromfreshlydissectedP21andP40RVMusing
Trizol (Sigma) as previously described [16], and the concentration
was determined using the ‘‘Nanodrop ND-1000’’ system (Nanodrop
Technologies). Sampleswere then diluted to an equal concentration
(1 lg/lL) and a 10-lg quantity was used to synthesize cDNA using
the InVitrogen Superscript First Strand Synthesis System for RT-
PCR kit. Speciﬁc primers for l-, j-, and d-opioid receptors were de-
signed and synthesized by Sigma-Genosys. An SYBR green-based
system (Applied Biosystems) was used for ampliﬁcation and detec-
tion. The ampliﬁcation process was monitored with Opticon Moni-
tor v3.1.32 software (M.J. Genework Inc Waltham Mass), and
ampliﬁcation was normalized to b-actin housekeeping gene.
The quantitative polymerase chain reaction primer sequences
were as follows: j-opioid receptor primer sense SKOR1: gac-
ttctgcttccccattaagatg and antisense AKOR1: ttattcatcccacccacatccc,
derived from sequence accession number D16829; d-opioid recep-
tor primers sense SDOR1: atctgggtcttggcttcagg and antisense
ADOR1: ccatagcacacggtgatgatg, derived from sequence accession
number U00475; l-opioid receptor primers sense SMOR1: tcacca-
gatattcaccctctg and antisense AMOR1: cgttgacgattttggcatttcg, de-
rived from sequence accession number L22455; and b-actin
primers sense SA1: agattactgccctggctccta and antisense AA1:
aggatagagccaccaatccac, derived from sequence accession number
NM-031144.
2.7. Data analysis and statistics
EMG data were normally distributed, and comparisons were
made between the baseline value of the AUC and those obtained
following RVM manipulation. Statistical comparisons between
the time points, or stimulation intensities post RVM manipulation
were achieved using a one-way analysis of variance (ANOVA) with
Dunnet’s post-test. Comparisons of drug effects in dose–response
studies were made using 2-way ANOVA with Bonferroni post-tests.
Comparisons between control and drug treated groups were
achieved using a Student’s t test. Behavioural data were not nor-
mally distributed and were analysed with a Kruskal–Wallis test
with a post-hoc Dunn’s multiple comparison test. Immunohisto-
chemical comparisons were made using an unpaired t test.
3. Results
3.1. l-Opioid receptor activation in the RVM facilitates nociceptive
reﬂexes in juvenile rats and inhibits them in adults
Opioid receptor activation of brainstem descending pathways
inhibits spinal nociceptive circuits in adult rats [22,35]. Because
descending control from the rostroventral medulla (RVM) under-
goes marked functional changes in postnatal life [18], we tested
whether there are differences in the effects of brainstem opioid
activation upon spinal nociceptive reﬂexes between young and
adult rats. In these experiments, nociceptive reﬂex excitability
was measured from the EMG activity of ﬂexor hindlimb muscles
evoked by mechanical stimulation of the plantar hindpaw. As ex-
pected, microinjection of the l-opioid receptor agonist DAMGO
(3, 10, and 30 ng) into the RVM of lightly anaesthetized adult rats
dose-dependently decreased spinal nociceptive reﬂex excitability
(Fig. 2A). When the same experiment was performed in preadoles-
cent rat pups (postnatal day 21 [P21]), the pattern of opioid recep-
tor-mediated descending control was different; microinjection of
Fig. 2. Activation of l-opioid receptors in the RVM has differential effects on spinal excitability depending on age. (A) DAMGO microinjected into the RVM of lightly
anaesthetised rats elicited dose-dependent inhibition of spinal nociceptive reﬂex activity in the adult rats (P40; circles) but facilitation in preadolescent rats (P21; squares).
The effect of DAMGO was signiﬁcantly different when the 2 age groups were compared and the inhibitory and facilitatory actions of the drug were signiﬁcant at 10 and 30 ng
in both age groups (P < 0.001 for overall response to DAMGO across doses in both age groups (F1,16 = 34.73). (B) Identical investigations using the d-opioid receptor agonist
D[Ala]-deltorphin II, fails to show any signiﬁcant age-related difference with analgesia being observed in both groups. (C) Intra-RVM microinjection of DAMGO (30 ng) had a
signiﬁcant effect on the von Frey hair threshold in EMG experiments. There was a signiﬁcant effect of age upon mechanical threshold (two-way ANOVA, F1,11 = 278.8,
P < 0.0001). Note that the basal mechanical thresholds in the adult and preadolescent groups are different; this is consistent with previous studies showing that mechanical
and thermal thresholds are lower early in life [14]. In adult rats, thresholds increased signiﬁcantly from baseline (⁄⁄⁄P < 0.001, ⁄P < 0.05, Bonferroni post-test) for 30 minutes
after drug microinjection. However, in preadolescent (P21) rats, thresholds decreased signiﬁcantly from baseline (⁄⁄⁄P < 0.0001, Bonferroni post-test), and this effect was
maintained for at least 40 minutes after DAMGO injection. (D) The ability of 30 ng DAMGO to facilitate juvenile responses was completely reversed by s.c. naloxone
hydrochloride (2 mg/kg) but was unaffected by saline [t(6) = 4.099, P < 0.05].
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ceptive reﬂex excitability (Fig. 2A). The enhanced reﬂex activity
seen in preadolescent rats is not an effect of repeated testing as
D[Ala]-deltorphin II, a d-opioid receptor agonist (30, 300, and
1000 ng) did not produce age-dependent differences in excitabil-
ity (Fig. 2B). Changes in reﬂex excitability were accompanied by a
parallel change in mechanical threshold in both adults and pread-
olescents. In adult rats, vFh threshold signiﬁcantly increased
10 minutes after DAMGO (30 ng) microinjection into the RVM
(Fig. 2C). This increase was maintained for 30 minutes post-drug
application. In preadolescent rats, however, a signiﬁcant reduc-
tion in threshold accompanied the increase in reﬂex excitability.
The reduction in threshold was apparent at 10 minutes after
DAMGO (30 ng) and was maintained for at least 40 minutes after
drug administration (Fig. 2C). To further assess whether the abil-
ity of DAMGO to facilitate preadolescent responses was due to
non-l-opioid receptor-mediated events, we tested whether the
effects were reversed by opioid-receptor antagonism. Systemic
application of the opioid receptor antagonist naloxone (2 mg/kg,
s.c.) completely abolished the facilitatory effect of DAMGO
(30 ng) on spinal nociceptive reﬂex excitability in young rats
(Fig. 2D).
To ensure that the facilitatory effect of brainstem l-opioid
receptor activation in young rats was speciﬁc to the RVM, control
microinjections of DAMGO (30 ng) were made into adjacent areas
of the brainstem (see Supplementary Fig. 1). These microinjections
had no effect upon nociceptive reﬂex activity (data not shown).To investigate whether the facilitatory effect of DAMGO was
secondary to a developmental change in inhibitory neurotransmis-
sion, the GABAA receptor antagonist gabazine (10 ng) was injected
into the RVM of adult and preadolescent rats. In rats of both ages,
gabazine inhibited spinal reﬂex excitability, signiﬁcantly reducing
evoked EMG excitability (Supplementary Fig. 1). Thus, the facilita-
tion of spinal excitability observed upon activating immature RVM
l-opioid networks is not secondary to a shift in RVM GABAA neu-
rotransmitter systems.
Together these experiments show that activation of l-opioid
receptors in the RVM facilitates spinal nociceptive reﬂexes in pre-
adolescent rats, although the same activation inhibits nociceptive
reﬂexes in adult rats.
3.2. Nociceptive reﬂexes in preadolescence are under tonic l-opioid
receptor facilitatory control, mediated at least in part, by the RVM
Although the experiments above show that exogenous activa-
tion of RVM l-opioid receptors facilitates nociceptive reﬂexes in
preadolescent rats, they do not indicate whether descending excit-
atory control is a normal feature in young rats. If there is tonic
descending excitation in naive preadolescent rats that is mediated
by endogenous opioids in the brainstem, local administration of l-
opioid antagonists to the RVM should reduce the magnitude of
baseline nociceptive reﬂexes.
To test this, we microinjected the speciﬁc l-opioid receptor
antagonist CTOP (100 ng) into the RVM of lightly anaesthetised
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antagonizing RVM l-opioid receptors upon the nociceptive reﬂex
excitability in adult and P21 rat pups. Although adult responses
were not affected, the response in preadolescent rats was signiﬁ-
cantly reduced (52% ± 12%, P < 0.01, t(8) = 4.135 vs adult).
The presence of a tonic endogenous opioid-mediated facilita-
tion of spinal nociception in juvenile rats was also observed upon
application of systemic l-opioid antagonists to freely behaving
awake rats. Subcutaneous administration of CTOP (0.1 mg/kg) or
naloxone hydrochloride (2 mg/kg, i.p.) had no effect on the
mechanical threshold in adult rats (Fig. 3B). In preadolescent rats,
however, both CTOP and naloxone signiﬁcantly increased mechan-
ical thresholds 30 minutes after drug administration from a base-
line of 8 g to 11.25 ± 0.8 g after naloxone and 12.5 ± 0.9 g after
CTOP [H(4) = 23.89, P < 0.001, Kruskal–Wallis].Fig. 3. Tonic facilitation of spinal reﬂexes from the RVM by endogenous opioids in
preadolescent rats. (A) The l-opioid receptor antagonist CTOP (100 ng) had no effect
on adult reﬂex activity when microinjected into the RVM of lightly anaesthetised
rats, but signiﬁcantly inhibited reﬂex magnitude in P21 animals. This shows that
l-opioid receptor-dependent facilitation arises from the pre-adolescent RVM. (B) In
freely behaving adult rats, neither CTOP (0.1 mg/kg i.p.) nor naloxone hydrochloride
(2 mg/kg i.p.) signiﬁcantly affectedmechanical thresholds. (C) The same drugs at the
same doses in preadolescent rats mediated signiﬁcant increases in mechanical
threshold (⁄⁄P < 0.01, ⁄⁄⁄P < 0.001, Dunn’s multiple comparisons test).These experiments show that the preadolescent spinal cord is
under tonic descending facilitatory control, which is due at least
in part to endogenous opioid activity in RVM, and that this is not
present in the adult.
3.3. Endogenous opioid activity over a critical preadolescent period is
required for the functional maturation of supraspinal RVM inhibitory
pain control
The existence of a tonic l-opioid receptor-mediated activation
of the RVM that is developmentally regulated, suggests that endog-
enous opioids may play a trophic role in the RVM. We have previ-
ously shown that between the ages of P21 to P25, descending
control of the RVM upon spinal nociceptive circuits shifts from
excitation to inhibition, suggesting that, over this critical period,
RVM circuitry undergoes a key maturational change [18]. The dis-
covery of endogenous opioid activity in the preadolescent brain-
stem led us to hypothesise that the shift from supraspinal
facilitation to inhibition of spinal nociceptive pathways at this
age depends upon tonic endogenous opioid receptor activation.
Speciﬁcally we proposed that the period from P21 to P25 may be
a time when endogenous opioid activity has a critical trophic inﬂu-
ence over the maturation of brainstem descending control circuits.
To test this, rats were implanted with subcutaneous osmotic
mini-pumps containing naloxone hydrochloride at P14, P21, or
P28 and the drug delivered continuously for 7 days, after which
time the animals were allowed to mature until adulthood (P40).
Control rats were treated with chronic naloxone methiodide
(which does not cross the blood–brain barrier) at P21 for 7 days.
When the rats had reached adulthood, the functional status of
brainstem descending control was assessed in all groups. The inﬂu-
ence of descending RVM activation upon spinal nociceptive reﬂex
excitability was quantiﬁed by measuring EMG responses during
electrical stimulation (5–200 lA) of the RVM, as previously de-
scribed [18]. Fig. 4A shows the effect of graded electrical stimula-
tion of the RVM upon nociceptive reﬂex excitability in the P40
naloxone methiodide adult control group. The pattern of reﬂex
facilitation at low RVM stimulus intensities and inhibition from
50–200 lA is exactly the same as that described for naive P40
(adult) rats [18], showing that chronic naloxone methiodide, which
does not cross the blood–brain barrier, has had no effect upon the
normal development of RVM descending controls.
The responses of animals treated with naloxone hydrochloride
between P21 and P28 were signiﬁcantly different (main effect of
treatment, 2-way repeated-measures ANOVA, F1,12 = 7.28,
P = 0.0194). Fig. 4B shows that chronic opioid receptor blockade
over P21 to P28 led to reﬂexes that were signiﬁcantly facilitated
at all RVM stimulation intensities tested. This pattern, never ob-
served in normal adult animals, resembles the descending control
in younger P21 animals [18]; no inhibition of EMG activity by RVM
stimulation was observed at any stimulation intensity. This failure
of descending inhibition to mature occurred only if endogenous
opioid activity was blocked over the postnatal week 4 (P21–28).
Descending inhibition developed normally if rats were implanted
with naloxone hydrochloride osmotic mini-pumps 1 week earlier,
P14–P21 (Fig. 4C) or 1 week later (P28–P33) (Fig. 4D).
To conﬁrm that systemic naloxone is a potent opioid antagonist
over the developmental period of these experiments, we showed
that naloxone HCL (2 mg/kg, i.p.), but not naloxone methiodide
(2 mg/kg, i.p.), reversed morphine analgesia in freely behaving pre-
adolescent rats (Supplementary Fig. 2). Furthermore, immuno-
staining in adult rats that had been treated with chronic
naloxone between P21 and P28, revealed no difference in l-opioid
expression in the RVM compared with saline controls (Fig. 5A and
B). In addition, the level of expression of l-, d-, and j-opioid
receptor mRNA in normal preadolescent and adult rat RVM was
Fig. 4. Endogenous opioid activity is required for the maturation of descending
control of nociception. Bar charts showing the change in spinal nociceptive reﬂex
excitability produced by electrical stimulation of the RVM (500 lsec, 5–200 lA,
10 Hz) in lightly anaesthetised adult rats. In each case, rats had undergone chronic
administration of naloxone (3 mg/kg) via s.c. implanted osmotic mini-pumps for 7
days at different periods of adolescence. (A) Control, naloxone methiodide, which
does not cross the blood–brain barrier, was administered between P21 and P28.
This had no effect on the maturation of RVM descending control of nociceptive
reﬂexes, with a signiﬁcant effect of RVM stimulation compared to basal EMG
responses (F6,5 = 17.19, P < 0.0001). (B) Chronic blockade of endogenous opioids
from P21 to P28. Naloxone hydrochloride, which does cross the blood–brain barrier,
was administered between P21 and P28. Descending inhibition, normally observed
in adults at higher RVM stimulation amplitudes, has not developed (basal vs RVM
stimulation, F6,7 = 7.456, P < 0.0001). (C) Chronic blockade of endogenous opioids
with naloxone hydrochloride, from P14 to P21. Descending inhibition has devel-
oped as normal (basal vs RVM stimulation, F6,5 = 15.06, P < 0.0001). (D) Chronic
blockade of endogenous opioids with naloxone hydrochloride, from P28 to P35
(basal vs RVM stimulation, F6,7 = 17.19, P < 0.0001). Descending inhibition has
developed as normal. Bars indicate standard error of the mean. Asterisks indicate
that stimulation amplitudes are signiﬁcantly different from baseline in Bonferroni
post-test. ⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001.
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and was found to be the same (Fig. 5C).
Together, these results show that postnatal week 4, which is the
preadolescent stage in rats, represents a critical period during
which endogenous activation of CNS opioid receptors is requiredto establish the normal balance of RVM descending inhibitory con-
trol of spinal pain circuits.
3.4. Chronic morphine administration in early life accelerates the
maturation of RVM inhibitory pain control
The results here show that endogenous activation of CNS opioid
receptors during a critical period of preadolescence is required for
RVM maturation. We next hypothesised that excessive activation
of the same receptors by chronic administration of exogenous opi-
oids before this critical periodmight therefore accelerate thismatu-
ration. To test this, we administered low doses (0.175 mg/kg) of
morphine sulphate via osmoticmini-pumps for 7 days in the second
postnatal week (P7–P14) and then measured the RVM descending
control of spinal nociceptive reﬂexes 1 week later, at P21. In normal
rats of this age, RVMmicrostimulationevokes amonophasic facilita-
tion of nociception over the range of stimulation amplitudes tested
(see Hathway et al. [18]). However, as shown in Fig. 6A, rat pups ex-
posed to excess exogenous opiates over the second postnatal week
had developed precociously, and signiﬁcant descending inhibition
could also be evoked at higher stimulus intensities. This pattern is
normally only observed in older animals of P25 or more [18]. A con-
trol group in which animals of the same age were implanted with
mini-pumps containing saline was included in this study (Fig. 6B)
and there was a signiﬁcant difference between these animals and
those treated with morphine (2-way repeated-measures ANOVA,
morphine vs saline, F1,11 = 7.29, P = 0.0223). Saline-treated animals
at this age failed to exhibit any descending inhibition. These data
show that the normal development of supraspinal RVM control of
spinal nociceptive circuits depends on the opioid receptor-mediated
activity in the brain in preadolescent life.4. Discussion
The involvement of supraspinal centres in the modulation of
nociception has been recognised for more than 50 years, since the
work of Hagbarth and Kerr [17]. The gate control theory of pain of
Melzack and Wall [27] was the ﬁrst clear articulation of the central
role of these descending pathways in processing noxious sensory
information, and since then it has become clear that endogenous
supraspinal mechanisms exert powerful control over spinal cord
pain circuits mediating such phenomena as placebo analgesia [10]
and playing a key role in the maintenance of chronic pain states
[29]. Although there is increasing understanding of the neuronal
networks and neurotransmitter systems that mediate descending
facilitatory and inhibitory control of pain (for reviews, see Fields
et al. [13] andZhuoandGebhart [46]), knowledge of how thesepath-
ways are established in early life and their functional maturation
through adolescence is lacking. This is surprising when it is consid-
ered, that once hospitalised, children are just as likely to undergo
painful procedures as adults, and that pain in early life can signiﬁ-
cantly alter sensory processing for a signiﬁcant period extending be-
yondmaturation and into later life [32,38,39]. In this study, we have
demonstrated that opioid receptor-mediatedactivationof circuits in
the RVM undergo signiﬁcant changes in the preadolescent period of
the rat. We have demonstrated that l-opioid receptor-mediated
descending activity from the immature RVM is pro-nociceptive,
and furthermore that spinal nociceptive circuits are under tonic opi-
oid receptor-mediated facilitation in preadolescence. After this
time, the tonic facilitation decreases and RVM l-opioid receptor-
mediated responses become anti-nociceptive in the adult. Sufﬁcient
levels of endogenous opioids during a critical period of development
are essential to this maturational process, and if opioid activity is
blocked between P21 and P28, the normal adult pattern of supraspi-
nal pain control fails to mature.
Fig. 5. l-Opioid receptor expression does not differ between ages or between rats chronically treated with s.c. naloxone or saline. (A) Immunohistochemical staining of the
RVM from adult animals treated with naloxone hydrochloride for 7 days via osmotic mini-pumps between P21 and P28 (top) and those given chronic saline over the same
period (bottom) shows that the drug treatment has no effect on l-opioid receptor expression pattern or number of l-opioid receptor expressing cells (arrows). Dotted line
demarcates the border of the nucleus raphe magnus. (B) There are no differences in the number of l-opioid receptor expressing neurones between the treatment groups
(n = 4 per group). (C) Reverse transcription-polymerase chain reaction from rat homogenates of rat RVM at postnatal day 21 and 40 show no differences in the expression
level of l-, d-, or j-opioid receptors (n = 4 per group). Mean intensity was normalised to b-actin.
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works having a key role in the maturation of descending control
over spinal nociceptive pathways. Microinjection of l-opioid
receptor agonists into the RVM resulted in dose-dependent
descending facilitation in young rats, which switched to inhibition
postnatal week 4. It is well established that RVM opioid signaling
has a key role in descending pain control; RVM neurons express
l-, j-, and d-opioid receptors, and their activation produces vari-
able degrees of analgesia [1,20,21]. Because ON cells are the only
physiologically deﬁned subpopulation of RVM cells to directly re-
spond to l-opioid receptor agonists [13,20], we can speculate that
it is this group of cells that undergo key developmental changes in
l opioid signalling; however, this requires more evidence. We
show that the consequences of activating RVM l-opioid receptorschanges dramatically during the late postnatal period. The fact that
DAMGO mediates its effects over the same dose range at P21 and
P40 suggests that the binding afﬁnities of the l-opioid receptor
do not alter with age. The differences that we have seen cannot
be attributed to diffusion of DAMGO to extra-NRM regions in youn-
ger brains, as comparisons of the preadolescent and adult brain
show that brains from these 2 age-groups are of similar size [18].
Our results show that the effects of the delta agonist, deltorphin,
in the RVM are not developmentally regulated, suggesting that
we have identiﬁed a selective change in l-opioid receptor-medi-
ated activity. This is reinforced by the ﬁnding that GABA-mediated
RVM inhibition is also unchanged, showing that the switch in l-
opioid receptor-mediated activity is not the result of an alteration
in RVM GABA signalling. The switch in opioid-mediated activity in
Fig. 6. Chronic morphine application in postnatal week 2 accelerates the matura-
tion of RVM descending control of nociception. (A) Histogram showing the change
in spinal nociceptive reﬂex excitability produced by electrical stimulation of the
RVM (500 lsec, 5–200 lA, 10 Hz) in lightly anaesthetised P21 rats that had
undergone chronic administration of morphine (0.175 mg/kg) via s.c. implanted
osmotic mini-pumps for 7 days between P7 and P14. In these animals, an adult
pattern of descending control has developed prematurely. (B) In control saline-
treated animals, facilitation was observed only at the age that is the case in normal
animals of this age [18]. Bars indicate standard error of the mean. Asterisks indicate
signiﬁcantly different from baseline in Bonferroni post-test. ⁄P < 0.05, ⁄⁄P < 0.01.
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pharmacology of this receptor at these different ages, but little is
known about this in the RVM. Recently, changes in brainstem l-
opioid receptor molecular weight have been reported during
development, which may have an impact on the binding properties
of the receptor; however, the functional implications of this are, as
yet, unclear [24]. In light of the data presented here, it is important
that future efforts be made to investigate the ability of the l-opioid
receptor to bind agonists and antagonists, and to study whether
the receptor is inserted and internalised from the cell membrane
in the same way at all ages.
The fundamentally different functional consequences of RVM l-
opioid receptor activation at P21 and P40 is shown by the effects of
l-opioid receptor antagonism with CTOP, which inhibited nocicep-
tive activity at P21 but had no effect at P40. Evidently, tonic ongo-
ing activation of l-opioid receptors by endogenous opioids occurs
in the young RVM that is not present in adulthood. The postnatal
period in both humans and animals is characterised by signiﬁ-
cantly lower mechanical and thermal pain thresholds, as well as
by exaggerated and inappropriate responses to noxious stimuli
[14]. This increased excitability has long been considered to be
shaped by a lack of inhibitory neurotransmission within the spinal
dorsal horn [2], much of which is intrinsic from GABA- and glycin-
ergic spinal interneuronal populations. The data presented here
highlight the important role of descending pathways in postnatal
development; the presence of a tonic facilitation arising from
endogenous opioid activation of RVM circuits in young animals is
likely to make a major contribution to the excitability of spinal
nociceptive circuits in young animals [15,18]. Nociceptive reﬂex
and dorsal horn cell-receptive ﬁelds in young rats have low
mechanical thresholds, large response amplitudes, and durations,
and mature to the adult form only after P21 [14]. One might spec-ulate that this enhanced excitability maximizes sensory input to
the CNS, thus contributing to the activity-dependent tuning of
spinal and supraspinal nociceptive circuits [7,30].
It is well known that neuronal circuits in the brain are shaped by
experience during ‘critical periods’ in postnatal life. Activity-depen-
dent development can be triggered by a variety of stimuli, depend-
ing on the brain region. Here we show, for the ﬁrst time, that the
development of brainstem descending pain pathways has a critical
period in postnatal week 4, relatively late in postnatal life. Impor-
tantly, this is a period during which opioid signalling is required
for the shift from descending facilitation to inhibition to take place.
Discovery of this critical period helps to explain how early exposure
to pain and injurymay have long-termeffects on sensory processing
in later life. Neonatal injury and stress inﬂuences future pain pro-
cessing both at the site of injury and globally, across thewhole body
[31,32]. Noxious stimuli cause release of endogenous opioids in a
number of CNS regions [3,40]. Such a change in opioid signaling in
the RVM around the critical period of postnatal development could
permanently alter CNS pain processing by altering the normal bal-
ance of descending control over spinal pain networks. In support
of this proposal, chronic administrationofmorphineover the second
postnatal week accelerated thematuration of RVM descending con-
trols. The recent report that neonatal injury can signiﬁcantly alter
opioidergic tone in adult PAG further supports a central role of opi-
oids in setting the level of descending control of pain [25].
The tonic facilitation of nociceptive pathways by endogenous
opiates in preadolescent rats might appear paradoxical, as mor-
phine is an effective analgesic in young animals [36], but this is
not so. Systemic morphine acts at many l-receptor sites in the ner-
vous system, at the level of the spinal cord, on C-ﬁbre afferent ter-
minals, and on numerous sites in the CNS, including the
periaqueductal grey and other brainstem nuclei, mediated by dis-
tinct mechanisms [41]. Lesion experiments have emphasised the
difference between sites of action for endogenous opioids and for
systemic morphine [42]. Supplementary Fig. 2 shows that nalox-
one hydrochloride is able to reverse the increase in threshold elic-
ited by systemic morphine in juvenile rats, and these data also
suggest that peripherally restricted naloxone methiodide is also
able to do the same. However, the naloxone methiodide data are
not signiﬁcantly different from any of the other groups in this
study, implicating central rather than peripheral opioid receptors
in morphine anti-nociception in juvenile rats.
We have shown that the preadolescent rat has an endogenous
l-opioid-mediated descending pain control system, which is toni-
cally active and which facilitates rather than suppresses pain trans-
mission. As the system matures, so the effects of activating this
pain control system become increasingly inhibitory, so that excita-
tion and inhibition are more ﬁnely balanced. We have also shown
that the emergence of this balanced pain control is dependent on
normal levels of activity in CNS opioid networks over a critical pre-
adolescent period. This provides an explanation for individual dif-
ferences in pain susceptibility based upon early life experience,
whereby alterations in endogenous opioid levels at a critical stage
of preadolescent life can shape top-down pain control in adult life.Conﬂicts of interest statement
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